Drug
Kn3835
Kn3835: highest development phase Phase 3, developed by Endo USA Inc., a Keenova Therapeutics Company. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Endo USA Inc., a Keenova Therapeutics Company
Trials
| Drug | Phase | Indication |
|---|---|---|
| KN3835 NCT07759362 | Phase 3 | Flexible Hammertoe |
Latest
No recent events.
Follow Kn3835 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.